Mounjaro's Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib
4 Articles
4 Articles
Mounjaro's Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib
(MedPage Today) -- The FDA expanded the indication for tirzepatide (Mounjaro) to include reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes, Eli Lilly announced. Global type 1 diabetes prevalence...
Mounjaro is the first and only GIP and LPG-1 receptor agonist to have been shown to reduce the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes and at high risk of such events, in addition to its consolidated benefits in terms of A1C control and weight loss
The U.S. Food and Drug Administration (FDA) has approved the use of Mounjaro to reduce the risk of heart attack and stroke in adults with type 2 diabetes and high cardiovascular risk. The decision was announced on Friday (August 28, 2026). This expands the use of the drug from the pharmaceutical company Eli Lilly, which was already authorized for glucose control in patients with the same condition. The FDA's approval was based on the results of …
The FDA, a US food and medicine regulatory agency, approved on Friday (28) the use of Mounjaro, from Eli Lilly to reduce the risk of stroke or stroke in high-risk patients with type 2 diabetes, marking the latest advance in the race between GLP-1 drug manufacturers to expand its use. Read more (09/01/2026
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
